Weight-loss drug firm accused of prioritising profits after halting insulin pen production

Novo Nordisk’s decision will force people in developing countries to use outdated glass vials and syringes, warn campaigners

The pharmaceutical company behind injectable weight-loss drugs has been accused of prioritising profits over the health of people in developing countries by halting production of its insulin pens.

People living with type 1 diabetes who are reliant on the human insulin produced by Novo Nordisk, will instead be given glass vials and syringes – which they say are inconvenient and harder to use with the same accuracy.

Continue reading…

About Author